证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2023-024 上海海欣集团股份有限公司 重要内容提示： 一、交易概述 2023 年 9 月 25 日，公司第十届董事会第三十次会议审议通过《关于转让上 海海欣医药股份有限公司股权的议案》，同意海欣资产向惠生云健转让持有的海 欣医药 51.3249%股权，交易方式为协议转让，交易价格为 2,304.94 万元，并授权 公司经营层具体办理股权转让事宜。具体内容请参见公司于 2023 年 9 月 26 日在 上海证券交易所（http://www.sse.com.cn）披露的《上海海欣集团股份有限公司关 于转让上海海欣医药股份有限公司股权的公告》（公告编号：2023-023）。 1 上海海欣集团股份有限公司（以下简称"公司"）全资子公司上海海欣资 产管理有限公司（以下简称"海欣资产"）将其持有的上海海欣医药股份 有限公司（以下简称"海欣医药"）51.3249%股权以 2,304.94 万元转让 给重庆惠生云健商务信息咨询中心（有限合伙）（以下简称"惠生云健"）。 当前海欣医药已完成股份变更登记，海欣资产不再持有海欣医药股权。 截至本 ...

证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2023-022 上海海欣集团股份有限公司 一、董事会会议召开情况 （一）本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定； （二）本次董事会会议通知于 2023 年 9 月 20 日以书面方式向全体董事发出，会 议资料于 2023 年 9 月 20 日以书面方式向全体董事发出； （三）本次董事会会议于 2023 年 9 月 25 日通讯表决方式召开； 第十届董事会第三十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经董事会审议，同意上海海欣资产管理有限公司向重庆惠生云健商务信息咨询中 心（有限合伙）转让持有的上海海欣医药股份有限公司 51.3249%股权，交易方式为协 议转让，交易价格为 2,304.94 万元，并授权公司经营层具体办理相关事宜。 具体请见同日披露的《上海海欣集团股份有限公司关于转让上海海欣医药股份有 限公司股权的公告》。 特此公告。 上海海欣集团股份有限公司 董 事 会 20 ...

证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2023-023 上海海欣集团股份有限公司 关于转让上海海欣医药股份有限公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 （一）交易基本情况 公司全资子公司海欣资产拟将其持有的海欣医药 51.3249%股权转让给重药 控股股份有限公司（以下简称"重药控股"）下属的惠生云健。本次交易以上海 东洲资产评估有限公司《评估报告》（东洲评报字【2023】第 2044 号）中海欣医 1 上海海欣集团股份有限公司（以下简称"公司"）全资子公司上海海欣资 产管理有限公司（以下简称"海欣资产"）拟将持有的上海海欣医药股份 有限公司（以下简称"海欣医药"）51.3249%股权以 2,304.94 万元转让 给重庆惠生云健商务信息咨询中心（有限合伙）（以下简称"惠生云健"）， 转让后，海欣资产不再持有海欣医药股权。 本次交易不构成关联交易。 本次交易不构成重大资产重组。 本次交易已经公司第十届董事会第三十次会议审议通过，无需 ...

证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2023-021 上海海欣集团股份有限公司 关于参加上海辖区上市公司 2023 年投资者 网上集体接待日活动暨中报业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 会议召开时间：2023 年 9 月 7 日 14:00-16:30 会议召开地点："全景路演"网站（网址 http://rs.p5w.net） 会议召开方式：网络互动交流 投资者可在本次活动召开前，扫描本公告中的二维码，提前留言提问。公司将在 业绩说明会期间对投资者普遍关注的问题进行回答。 上海海欣集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日披露公 司 2023 年半年度报告。为进一步加强与投资者的互动交流，公司将参加由上海证监 局、上海上市公司协会与深圳市全景网络有限公司联合举办的 2023 年上海辖区上市 公司集体接待日活动暨中报业绩说明会，就投资者关心的问题进行交流。 1 一、说明会类型 本次说明会将以网络互动形式召开，公司将针对 2023 年半年度经营 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥625.16 million, a decrease of 1.78% compared to ¥636.51 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥101.68 million, down 18.80% from ¥125.22 million in the previous year[21]. - The basic earnings per share for the first half of 2023 was ¥0.0842, representing a decline of 18.80% compared to ¥0.1037 in the same period last year[20]. - The net cash flow from operating activities decreased by 64.12%, amounting to approximately ¥3.73 million compared to ¥10.39 million in the previous year[21]. - The company reported a decrease of 14.33% in net profit after deducting non-recurring gains and losses, amounting to approximately ¥104.42 million compared to ¥121.88 million in the previous year[21]. - The company achieved operating revenue of CNY 625.16 million, a year-on-year decrease of 1.78%[28]. - Net profit for the period was CNY 101.68 million, down 18.80% year-on-year[28]. - The company reported a significant decrease in sales expenses, which fell to CNY 190,262,248.25 from CNY 241,573,821.60[97]. - The net profit for the first half of 2023 was CNY 99,833,267, a decrease of 21.7% from CNY 127,346,935 in the first half of 2022[102]. - The total comprehensive income for the first half of 2023 was CNY 187,323,767.30, compared to a loss of CNY 172,354,564.22 in the first half of 2022[102]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥5.12 billion, an increase of 3.88% from the previous year's end[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥3.84 billion, reflecting an increase of 3.56% compared to the previous year[21]. - The company's total liabilities amounted to CNY 969,910,430.35, compared to CNY 911,215,769.39, marking an increase of around 6.05%[91]. - Total assets increased to CNY 5,230,032,587.68, up from CNY 5,050,661,992.87 at the end of the previous period[95]. - The company's total liabilities are not explicitly stated but can be inferred from the total equity and assets figures[115]. Segment Performance - The pharmaceutical segment generated CNY 357.81 million in revenue, a decline of 7.05% year-on-year, with net profit of CNY 9.28 million, down 15.84%[28]. - The property leasing segment reported rental income of CNY 49.19 million, an increase of 7.40% year-on-year, with operating net profit of CNY 25.17 million, down 6.60%[31]. - The textile segment's revenue was CNY 84.98 million, a decrease of 19.47% year-on-year, with a net loss of CNY 2.23 million[32]. Cash Flow - The net cash flow from operating activities for the first half of 2023 was -25,697,515.58 RMB, compared to -22,729,508.26 RMB in the same period of 2022, indicating a decline of approximately 13.0%[108]. - Cash and cash equivalents at the end of the period increased to 508,902,217.10 RMB, up from 373,386,172.34 RMB in the previous year, representing a growth of about 36.2%[106]. - The net cash flow from investing activities was 126,372,977.82 RMB, an increase of 62.5% compared to 77,667,369.67 RMB in the first half of 2022[109]. Shareholder Information - Total number of ordinary shareholders as of the end of the reporting period is 65,429, with 33,754 A-share holders and 31,675 B-share holders[81]. - The largest shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 141,528,801 shares, representing 11.73% of total shares[83]. - The company has not reported any changes in share capital structure during the reporting period[80]. Environmental Compliance - The company is listed as a key pollutant discharge unit, with subsidiaries included in the environmental protection department's list[58]. - The company’s wastewater treatment standards have not exceeded the regulatory limits, indicating compliance with environmental standards[59]. - The company reported that particulate matter emissions from the workshop were below the standard limit of <120 mg/Nm3, indicating compliance with environmental regulations[61]. - The total nitrogen emissions from wastewater were measured at 4.357 mg/L, significantly below the regulatory limit of <30 mg/L[63]. - The company continues to monitor and ensure that all emissions remain within the regulatory limits, demonstrating a commitment to environmental responsibility[61]. Legal Matters - The company is actively following up on the litigation process regarding the equity exit lawsuit to protect its rights[48]. - The first-instance judgment in the creditor lawsuit against Baoding Haixin has been supported by the court, and the next step is to apply for the execution of the judgment[48]. - The company is preparing for a civil lawsuit initiated by China Construction Eighth Engineering Division regarding project settlement disputes, which is pending trial[48]. Strategic Initiatives - The company is actively disposing of low-efficiency assets to improve overall asset quality, with several subsidiaries being deregistered in 2023[33]. - The company is focusing on enhancing its core competitiveness in the pharmaceutical sector through increased R&D efforts[28]. - The company is transitioning its textile operations from a "production-oriented" model to a "R&D and trade-oriented" model[32]. Accounting Policies - The company's accounting policies comply with the relevant accounting standards, ensuring the accuracy and completeness of financial reporting[125]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those measured at fair value through other comprehensive income[166]. - The company uses the weighted average method for inventory cost calculation, which includes raw materials, direct labor, and manufacturing expenses allocated under normal production capacity[187].

证券代码：600851 证券简称：海欣股份 公告编号：2023-015 900917 海欣 B 股 上海海欣集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 04 日(星期四) 至 05 月 10 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600851@haixin.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 上海海欣集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发 布公司2022年度报告，并将于2023年4月29 日发布公司2023年第一季度报告。 为便于广大投资者更全面深入地了解公司2022年度及2023年第一季度经营成果、 财务状况，公司计划于 2023 年 05 月 11 日 上午 11:00-12:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥412,389,999.84, representing a year-over-year increase of 25.54%[6] - The net profit attributable to shareholders for Q3 2022 was ¥45,036,006.62, up 38.97% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,242,506.98, reflecting a 39.76% increase year-over-year[6] - Basic earnings per share for Q3 2022 were ¥0.0373, an increase of 38.66% compared to the same period last year[9] - Net profit for Q3 2022 was approximately $181.71 million, an increase of 18.3% from $153.68 million in Q3 2021[32] - Earnings attributable to shareholders of the parent company for Q3 2022 were approximately $170.25 million, compared to $149.42 million in Q3 2021, representing a growth of 13.9%[32] Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 81.97% to ¥40,002,254.43, primarily due to last year's significant sales revenue from land[13] - The net cash flow from operating activities was 40,002,254.43 CNY, a decrease from 221,925,345.73 CNY in the previous year[38] - Cash received from the sale of goods and services was 1,109,200,771.71 CNY, down from 1,134,547,722.96 CNY year-over-year[35] - The net cash flow from investing activities was 82,160,513.41 CNY, compared to -61,033,949.54 CNY in the same period last year[38] - The net cash flow from financing activities was -44,648,448.62 CNY, a significant decrease from -229,320,705.67 CNY in the previous year[41] - The cash and cash equivalents at the end of the period amounted to 404,489,751.26 CNY, up from 327,851,446.84 CNY year-over-year[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,923,564,274.79, down 7.55% from the end of the previous year[9] - As of September 30, 2022, total current assets amounted to RMB 1,075,691,951.08, an increase from RMB 913,297,707.32 as of December 31, 2021, reflecting a growth of approximately 17.8%[20] - Total non-current assets decreased to RMB 3,847,872,323.71 from RMB 4,412,321,763.20, a decline of about 12.8%[24] - The total assets of the company as of September 30, 2022, were RMB 4,923,564,274.79, down from RMB 5,325,619,470.52, reflecting a decrease of approximately 7.6%[24] - Total liabilities decreased to approximately $946.99 million in Q3 2022 from $1.04 billion in Q3 2021, a reduction of about 9.2%[26] - Total equity decreased to approximately $3.98 billion in Q3 2022 from $4.28 billion in Q3 2021, a decline of about 7.0%[26] Shareholder Information - The company reported a total of 32,597 ordinary shareholders at the end of the reporting period[14] - The company's total liabilities included accounts payable of RMB 77,408,896.01, down from RMB 86,148,125.53, indicating a decrease of approximately 10.1%[24] - The company reported a decrease in other payables to RMB 229,306,460.97 from RMB 171,612,883.40, which is an increase of about 33.5%[24] Research and Development - Research and development expenses for Q3 2022 were approximately $13.96 million, slightly down from $14.53 million in Q3 2021[30] - The company has not indicated any new product launches or technological advancements during the reporting period[20] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 1.3848%, an increase of 0.6352 percentage points year-over-year[9] - The company recorded non-recurring gains and losses totaling -¥206,500.36 for the reporting period[10] - The company's deferred income tax liabilities were approximately $416.42 million in Q3 2022, down from $560.99 million in Q3 2021, a reduction of about 25.7%[26] - The total comprehensive income attributable to the parent company was -259,405,671.43 CNY, compared to 8,800,430.63 CNY in the same period last year[35] - The total cash inflow from investment activities was 737,641,448.98 CNY, compared to 635,085,398.84 CNY in the previous year[38] - The cash outflow for purchasing fixed assets and intangible assets was 10,963,610.92 CNY, significantly lower than 69,121,609.34 CNY in the previous year[38] - The company received 10,276,387.42 CNY in tax refunds, an increase from 7,925,638.16 CNY in the same period last year[35]

2022 年第一季度报告 证券代码：600851 证券简称：海欣股份 900917 海欣 B 股 上海海欣集团股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------|----------------|-------|-------------------------------------| | | | | 单位：元 币种：人民币 | | 项目 | 本报告期 | | 本报告期比上年同期 ...

Financial Performance - Net profit attributable to shareholders increased by 80.56% to CNY 23,673,138.64 year-on-year, driven by increased investment income from Changxin Fund and Suzhong Pharmaceutical[11] - Operating revenue rose by 37.53% to CNY 254,199,834.90, primarily due to increased sales from Jiangxi Gannan Haixin Pharmaceutical Co., Ltd.[11] - Basic earnings per share increased by 79.82% to CNY 0.0196 compared to the previous year[11] - The weighted average return on equity improved by 0.2234 percentage points to 0.5635%[11] - Total operating revenue for Q1 2021 was $254.20 million, up from $184.83 million in Q1 2020, representing an increase of 37.4%[43] - Net profit for Q1 2021 was $23.42 million, significantly higher than $9.73 million in Q1 2020, marking an increase of 141.5%[45] - The total profit for the first quarter of 2021 was 18,755,740.79 CNY, compared to 12,977,921.37 CNY in the same period of 2020, representing an increase of approximately 44%[50] - The net profit for the first quarter of 2021 was 18,755,740.79 CNY, showing a significant improvement from a net loss in the previous year[50] Cash Flow - Net cash flow from operating activities reached CNY 75,419,564.92, a significant improvement from a negative CNY 16,268,112.59 in the same period last year[11] - Cash received from sales of goods and services increased by 42.19% to ¥325,237,950.47, compared to ¥228,736,899.93 in the previous year[21] - Cash flow from operating activities for the first quarter of 2021 was 75,419,564.92 CNY, a turnaround from a negative cash flow of -16,268,112.59 CNY in the first quarter of 2020[53] - The total cash and cash equivalents at the end of the period were $109.68 million, down from $173.47 million in the previous year[59] Assets and Liabilities - Total assets decreased by 5.74% to CNY 5,302,010,685.76 compared to the end of the previous year[11] - Current liabilities totaled ¥515,744,048.48, an increase from ¥497,377,650.81, driven by higher employee compensation and other payables[31] - Total liabilities increased from ¥1,245,567,071.88 to ¥1,145,786,469.55, a decrease of approximately 8.03%[33] - Total equity decreased from ¥4,379,498,999.59 to ¥4,156,224,216.21, a decline of about 5.09%[33] - The company's total equity attributable to shareholders decreased from ¥4,189,071,328.66 to ¥3,963,052,618.56, a decline of about 5.40%[33] Expenses - Sales expenses surged to ¥122,758,917.51, up 188.33% from ¥42,576,466.11, primarily due to increased product promotion costs[21] - Cash paid for taxes increased by 51.46% to ¥25,020,310.23, up from ¥16,519,622.26, mainly due to higher value-added tax payments[21] - Cash paid for other operating activities rose by 43.70% to ¥76,859,894.09, compared to ¥53,487,042.98, primarily due to increased product promotion expenses[21] - Research and development expenses decreased to $2.90 million in Q1 2021 from $3.69 million in Q1 2020, a reduction of 21.4%[43] Shareholder Information - The total number of shareholders at the end of the reporting period was 64,976, with the top ten shareholders holding a significant portion of shares[18] - The largest shareholder, Shenzhen Ningrui Investment Management Partnership, held 141,528,801 shares, accounting for 11.73% of total shares[18] Other Financial Information - The company reported a non-operating income of CNY 1,307,557.87, which includes various gains and losses[14] - The company has not disclosed any new product developments or market expansion strategies in this report[19]

2020 年年度报告 公司代码：600851 公司简称：海欣股份 900917 海欣 B 股 上海海欣集团股份有限公司 2020 年年度报告 1 / 176 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 众华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司董事长费敏华、总裁黄源、主管会计工作负责人朱锡峰及会计机构负责人（会计主管人 员）蔡晓斐声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经审计，2020年度公司实现归属于上市公司股东的净利润为119,391,753.57元，加上其他转 入678,238.79元，按照母公司实现的净利润提取10%的法定盈余公积金14,259,674.40元，加上年 初未分配利润449,434,193.70元，扣除应付2019年普通股股利36,211,700.76元，本年度末未分配 利润为519,032, ...